Financial Performance - Operating revenue for the first quarter of 2025 reached CNY 41,114,179.92, representing a year-on-year increase of 20.95%[11] - Net profit attributable to shareholders for the first quarter was CNY 3,160,478.97, an increase of 75.91% compared to the same period last year[11] - The basic earnings per share for the first quarter was CNY 0.04, up 75.91% from CNY 0.02 in the previous year[11] - Total operating revenue for Q1 2025 reached ¥41,114,179.92, a 21.5% increase from ¥33,991,989.13 in Q1 2024[33] - Operating profit for Q1 2025 was ¥3,881,217.75, up 50.5% from ¥2,581,973.37 in Q1 2024[34] - Net profit for Q1 2025 was ¥2,679,778.27, representing an 84.7% increase compared to ¥1,450,054.05 in Q1 2024[34] - Total profit for Q1 2025 was ¥3,869,240.43, an increase of 53.1% from ¥2,527,910.48 in Q1 2024[34] - The company’s total comprehensive income for Q1 2025 was ¥2,679,778.27, compared to ¥1,450,054.05 in Q1 2024[34] Cash Flow - The net cash flow from operating activities was CNY 2,364,783.10, reflecting a significant increase of 92.14% year-on-year[13] - Operating cash flow for Q1 2025 was CNY 2,364,783.10, a significant increase from CNY 1,230,747.10 in Q1 2024, reflecting improved operational efficiency[38] - Total cash inflow from operating activities was CNY 52,993,928.91 in Q1 2025, compared to CNY 55,191,185.81 in Q1 2024, indicating a decrease of approximately 3.9%[37] - Cash outflow from operating activities decreased to CNY 50,629,145.81 in Q1 2025 from CNY 53,960,438.71 in Q1 2024, a reduction of about 6.8%[37] - The company reported a net cash flow from operating activities of CNY 4,634,118.12 for the parent company in Q1 2025, compared to CNY 595,427.27 in Q1 2024, showing a substantial improvement[40] - Total cash inflow from operating activities for the parent company was CNY 38,972,833.30 in Q1 2025, up from CNY 35,469,028.65 in Q1 2024, reflecting an increase of about 7.1%[39] - Cash outflow from operating activities for the parent company was CNY 34,338,715.18 in Q1 2025, slightly down from CNY 34,873,601.38 in Q1 2024, indicating stable cost management[40] - The net cash flow from financing activities was negative CNY 1,315,270.54 in Q1 2025, compared to negative CNY 42,802,518.63 in Q1 2024, indicating improved financing conditions[38] Assets and Liabilities - Total assets as of March 31, 2025, amounted to CNY 472,560,164.18, a decrease of 1.77% compared to the end of 2024[11] - The company's asset-liability ratio decreased to 4.13% for the parent company and 13.31% for the consolidated entity, down from 5.77% and 15.41% respectively[11] - Total liabilities decreased from 74,131,206.41 to 62,921,187.30, a reduction of about 15.2%[29] - Current liabilities decreased from 57,654,611.13 to 45,088,321.43, a decrease of approximately 21.8%[28] - Non-current liabilities increased from 16,476,595.28 to 17,832,865.87, an increase of about 8.2%[28] - Shareholders' equity increased from 406,959,198.61 to 409,638,976.88, an increase of approximately 0.4%[29] - The total current assets decreased from ¥199,018,789.23 to ¥196,531,530.85, a decline of about 0.2%[30] - The total non-current assets increased from 219,950,383.83 to 221,171,356.68, an increase of approximately 0.6%[28] Research and Development - Research and development expenses increased by 44.00% to CNY 4,468,810.50, primarily due to higher personnel costs and depreciation[13] - Research and development expenses increased to ¥4,468,810.50 in Q1 2025, up 44.0% from ¥3,103,297.97 in Q1 2024[33] Shareholder Information - The total number of shares held by the top ten shareholders increased to 61,725,200, representing 75.8254% of the total shares[20] - The company has no pledged or judicially frozen shares among its major shareholders[21] - There were no significant legal disputes or external guarantees reported during the period[23] - The company has fulfilled all disclosed commitments in a timely manner as per the prospectus[23] - The company did not engage in any major acquisitions or asset sales during the reporting period[23] Other Financial Metrics - The company experienced a 301.07% increase in credit impairment losses, primarily due to accelerated collections of accounts receivable[13] - The company reported a credit impairment loss of ¥320,188.65 in Q1 2025, compared to ¥79,834.34 in Q1 2024[34] - Other income decreased significantly to ¥472,677.71 in Q1 2025 from ¥3,437,331.80 in Q1 2024[33] - Total operating costs for Q1 2025 were ¥37,789,209.81, a 9.0% increase from ¥34,730,985.29 in Q1 2024[33]

证券代码：871753 证券简称：天纺标 公告编号：2025-010 天纺标检测认证股份有限公司 第三届监事会第十次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 28 日 2.会议召开地点：公司会议室 3.会议召开方式：现场投票表决 4.发出监事会会议通知的时间和方式：2025 年 4 月 18 日 以书面送达会议通知方 式发出 5.会议主持人：王秀玮女士 6.召开情况合法、合规、合章程性说明： 本次监事会的召集、召开程序符合《公司法》等法律、法规、规章及《公 司章程》和《监事会议事规则》的规定，合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 依据公司监事会 2024 年度工作情况及公司年度经营状况，公司监事会组 织编写了《2024 年度监事会工作报告》。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.回避表决情况 本议案无需回避表决。 1.议案内 ...

Financial Performance - The company reported a total revenue of 81.4 million RMB for the fiscal year 2024, reflecting a year-on-year increase of 15%[21]. - The company's operating revenue for 2024 reached ¥217,410,317.28, representing a year-over-year increase of 10.95% compared to ¥195,956,814.03 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥28,745,445.31, reflecting a growth of 5.80% from ¥27,170,357.10 in 2023[23]. - The gross profit margin improved to 48.47% in 2024, up from 46.34% in 2023[23]. - The company reported a net profit growth rate of 2.42% for 2024, compared to a 5.15% growth rate in 2023[26]. - The company achieved a revenue of 217.41 million yuan in the reporting period, representing a year-on-year growth of 10.95%[39]. - The net profit attributable to shareholders of the listed company was 28.75 million yuan, an increase of 5.80% year-on-year[39]. - The cash flow from operating activities for 2024 was ¥49,978,275.32, a slight decrease of 1.13% from ¥50,547,213.93 in 2023[26]. Assets and Liabilities - The total assets decreased by 7.93% to ¥481,090,405.02 in 2024, down from ¥522,530,811.65 in 2023[25]. - The total liabilities increased by 11.23% to ¥74,131,206.41 in 2024, compared to ¥66,649,769.09 in 2023[25]. - The net assets attributable to shareholders decreased by 10.73% to ¥396,738,526.51 in 2024, down from ¥444,445,705.27 in 2023[25]. - Accounts receivable increased by 18.99%, from 66,345,294.91 yuan in 2023 to 78,946,826.39 yuan in 2024[41]. - Inventory rose by 81.92%, from 443,481.37 yuan in 2023 to 806,791.73 yuan in 2024, mainly due to increased bulk purchases of experimental consumables[43]. Research and Development - Research and development expenses increased by 30% to 10 million RMB, focusing on new testing technologies and methodologies[21]. - The company achieved R&D expenditures of ¥16,936,882.82, representing 7.79% of operating revenue, an increase from 7.17% in the previous period[74]. - The total number of R&D personnel increased from 105 to 178, with the proportion of R&D staff in total employees rising from 23.13% to 29.32%[75]. - The company holds a total of 86 patents, including 10 invention patents, up from 72 patents and 8 invention patents in the previous period[76]. - The company is developing several R&D projects, including a rapid non-destructive testing model for textile fiber components, which is currently in progress[77]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces in 2025, aiming for a 25% growth in regional revenue[21]. - The company has set a performance guidance for 2025, projecting a revenue target of 100 million RMB, which represents a 23% growth[21]. - The company successfully completed the acquisition of a local competitor, which is expected to enhance its service capabilities and market share by 15%[21]. - The company is focused on high-quality development and aims to enhance its capabilities in certification and inspection services in response to national economic strategies[88]. - The company intends to utilize capital market tools for mergers and acquisitions, aiming to integrate high-quality testing institutions and improve transparency in information disclosure[97]. Corporate Governance and Compliance - The company has implemented rigorous internal controls to ensure the accuracy of revenue recognition, which is a key performance indicator[82]. - The company has not faced any major litigation or arbitration matters during the reporting period, reflecting a stable legal standing[103]. - The company has not provided any external guarantees or loans, maintaining a conservative financial approach[102]. - The company has established effective internal control systems, ensuring compliance, asset security, and accurate financial reporting[171]. - The governance mechanism is designed to protect the rights of all shareholders, particularly minority shareholders[154]. Employee and Talent Management - The total number of employees increased from 454 to 607, representing a growth of approximately 33.6%[138]. - The number of technical staff rose from 376 to 483, an increase of 28.4%[138]. - The company has established a comprehensive employee training program to enhance skills and capabilities[140]. - The company is actively working on attracting and retaining core professional talent through effective incentive mechanisms and professional training programs[99]. - The total number of employees with a master's degree increased from 56 to 75, a growth of 33.9%[139]. Risk Management - The company has identified potential risks related to regulatory changes, which could impact operational procedures and compliance costs[21]. - There were no significant changes in major risk factors during the reporting period, indicating stability in the company's risk management[99]. - The management acknowledges that the achievement of business goals is subject to various uncertainties, including technological innovation and market changes[98]. Social Responsibility - The company actively engages in corporate social responsibility, ensuring timely salary payments and social security for employees, thereby enhancing employee welfare[86]. - The company emphasizes compliance with environmental laws and has implemented effective pollution control measures, ensuring that all emissions meet regulatory standards[87].

（一）会计师事务所基本情况 会计师事务所名称：中兴华会计师事务所（特殊普通合伙） 关于中兴华会计师事务所（特殊普通合伙） 2024 年度履职情况评估报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 天纺标检测认证股份有限公司（以下简称"公司"）聘请了关于中兴华会计 师事务所（特殊普通合伙）（以下简称"中兴华"）作为公司 2024 年年度审计 机构。根据《国有企业、上市公司选聘会计师事务所管理办法》《关于上市做好 选聘会计师事务所工作的提醒》等法律法规的要求，公司对中兴华在 2024 年度 审计过程中的履职情况进行了评估，具体情况如下： 一、会计师事务所基本情况 证券代码：871753 证券简称：天纺标 公告编号：2025-025 天纺标检测认证股份有限公司 2024 年度末合伙人数量：199 人 2024 年度末注册会计师人数：1052 人 2024 年度末签署过证券服务业务审计报告的注册会计师人数：522 人 2024 年收入总额（未经审计）：203,338.19 万元 成立日期：2013 年 1 ...

证券代码：871753 证券简称：天纺标 公告编号：2025-028 天纺标检测认证股份有限公司 关于同一控制下企业合并追溯调整财务数据的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、同一控制下企业合并情况 天纺标检测认证股份有限公司（以下简称"公司"）于 2024 年 1 月 12 日 召开第三届董事会第六次会议，于 2024 年 1 月 31 日召开 2024 年第一次临时股 东大会，审议通过了《关于终止发行股份及支付现金购买资产暨关联交易事项变 更为现金收购股份的议案》、《关于现金收购天津市乳品食品监测中心有限公司 100%股权暨关联交易的议案》，决议通过现金收购的方式，购买天津市乳品食品 监测中心有限公司 100%股权，并于 2024 年 2 月 2 日以自有资金 42,270,993.38 元支付了此股权转让款，乳品公司于 2024 年 2 月 4 日在天津市南开区市场监督 管理局已完成工商变更，成为公司的全资子公司。 根据《企业会计准则第 2 号-长期股权投资》、《企业会计准则第 ...

证券代码：871753 证券简称：天纺标 公告编号：2025-029 天纺标检测认证股份有限公司 内部控制自我评价报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合本公司（以下简称公司）《内部控制 手册》，在内部控制日常监督和专项监督的基础上，我们对公司内部控制有效性 进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。管理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：871753 证券简称：天纺标 公告编号：2025-016 天纺标检测认证股份有限公司 董事会关于独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《北京证券交易所股票上市规则》《北 京证券交易所上市公司持续监管指引第 1 号——独立董事》等相关规定要求，天 纺标检测认证股份有限公司（以下简称"公司"）董事会就在任独立董事王殿禄、 岳殿民、刘晓晖的对独立性情况进行评估并出具如下专项意见： 根据独立董事向董事会提交的关于独立性情况的自查报告，结合其他相关资 料，董事会就独立董事的独立性形成如下结论： （一）独立董事及其配偶、父母、子女、具有主要社会关系的人员未在公司 或公司附属企业任职； （六）独立董事不是为公司及公司控股股东、实际控制人或者其各自附属企 业提供财务、法律、咨询、保荐等服务的人员，包括但不限于提供服务的中介机 构的项目组全体人员、各级复核人员、在报告上签字的人员、合伙人、董事、高 级管理人员及主要负责人； — 1 — ...

证券代码：871753 证券简称：天纺标 公告编号：2025-027 天纺标检测认证股份有限公司 2024 年度董事会审计委员会履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《公司法》《证券法》《北京证券交易所股票上市规则》《公司章程》 及《董事会审计委员会议事规则》等相关规定，天纺标检测认证股份有限公司（以 下简称"公司"）董事会审计委员会本着勤勉尽责的原则，认真履行审计监督职 责，现将 2024 年度履职情况报告如下： 一、审计委员会基本情况 公司第三届董事会审计委员会由 3 名董事组成，分别为独立董事岳殿民、独 立董事刘晓晖、董事长葛传兵，其中，审计委员会主任委员由专业会计人士岳殿 民担任。 二、审计委员会 2024 年度会议召开情况 2024 年度，公司董事会审计委员会按照有关法律法规的要求，充分发挥审 查、监督作用，勤勉尽责地开展工作，为完善公司治理、提高内部审计和外部审 计工作质量发挥了重要作用，召开 5 次会议，具体情况如下： | 序 | | 届次 | 时间 | 议案 ...

证券代码：871753 证券简称：天纺标 公告编号：2025-031 天纺标检测认证股份有限公司 2025 年度董事、监事及高级管理人员薪酬方案 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 天纺标检测认证股份有限公司（以下简称"公司"）根据《公司法》《公司 章程》及相关法律、法规和规范性文件的规定，结合经营发展等实际情况，参考 行业、地区薪酬水平，制定了 2025 年度董事、监事及高级管理人员薪酬方案。 现将具体情况公告如下： 一、2025 年度董事、监事及高级管理人员薪酬方案 （一）适用对象 公司的董事、监事、高级管理人员 （二）适用期限 2025 年 1 月 1 日至 2025 年 12 月 31 日 （三）薪酬标准 1.公司董事薪酬方案 （1）公司非独立董事在公司担任管理职务者，根据其在公司所担任的管理 职务或岗位，按公司相关薪酬与绩效考核办法领取薪酬；未在公司担任管理职务 的非独立董事，不在公司领取薪酬或津贴。 （2）公司独立董事职务津贴为 4.8 万元/年（税前）。 2.公司监事薪酬方案 ...

TIAN 天纺标检测认证股份有限公司 TianFangBiao Standardization Certification & Testing Co.,Ltd. e 公司官网:https://www.cnttts.com ☎ 联系电话:4000-871753 |775 环境、社会和公司治理 (ESG) 报告 0 . 9 15 C 9 6 9 天纺标检测认证股份有限公司 TianFangBiao Standardization Certification & Testing Co.,Ltd. 2024 CONTENTS ■ 录 | 关于本报告 | 01 | | --- | --- | | 董事长致辞 | 02 | | ESG关键绩效表 | 75 | | --- | --- | | 报告编制标准索引表 78 | | | 反馈意见表 | 79 | 0 1 走进天纺标 | 公司简介 | 06 | | --- | --- | | 发展历程 | 07 | | 业务范围 | 09 | | 企业文化 | 11 | | 企业愿景 | 11 | | 股权架构 | 12 | | 中长期发展规划 | 13 | | 年度荣誉墙 | 1 ...